文献速递鼻科

鼻后神经射频神经松解术治疗慢性鼻炎的两年结局

Two-Year Outcomes After Radiofrequency Neurolysis of Posterior Nasal Nerve in Chronic Rhinitis.
PubMed 文献 · Laryngoscope · 2023-11-02

这项前瞻性单臂研究在16个中心纳入129例慢性鼻炎患者,评估温度控制射频(TCRF)鼻后神经(PNN)神经松解术的长期安全性和有效性。2年时rTNSS较基线改善-4.5(95%CI,-5.0至-3.9;p<0.001),80.0%患者达到最小临床重要差异(MCID),未报告器械/操作相关严重不良事件。

要点

  • 2年时rTNSS较基线改善-4.5(95%CI,-5.0至-3.9;p<0.001),改善57.7%。
  • 2年时80.0%患者达到rTNSS的MCID(较基线改善≥30%)。
  • 2年随访期间未报告器械/操作相关严重不良事件。

核心结论

  • TCRF鼻后神经神经松解术使慢性鼻炎症状负担和生活质量在2年内持续改善,并伴随用药负担大幅降低。

研究设计与样本

  • 前瞻性单臂研究,在美国和德国的16个中心纳入129例患者。
  • 患者报告结局指标为24小时回顾性鼻部症状总分(rTNSS)和迷你鼻结膜炎生活质量问卷(MiniRQLQ)。
  • 鼻后滴漏和咳嗽症状采用4分制评估。

主要发现

  • 治疗前平均rTNSS为7.8(95%CI,7.5-8.1)。
  • 3个月时rTNSS治疗效应显著为-4.2(95%CI,-4.6至-3.8;p<0.001),并持续至2年(-4.5[95%CI,-5.0至-3.9];p<0.001),改善57.7%。
  • 2年时rTNSS较基线改善≥30%的MCID达标患者比例为80.0%(95%CI,71.4%-86.5%)。
  • 鼻后滴漏和咳嗽单项症状评分从基线至2年显著改善。
  • 2年时MiniRQLQ的MCID(改善≥0.4分)达标患者比例为77.4%(95%CI,68.5%-84.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the long-term safety and effectiveness of temperature-controlled radiofrequency (TCRF) neurolysis of the posterior nasal nerve (PNN), a minimally invasive treatment for chronic rhinitis. METHODS: A prospective, single-arm study of 129 patients at 16 centers (United States, Germany) was conducted. Patient-reported outcome measures were the 24-h reflective total nasal symptom score (rTNSS) and mini rhinoconjunctivitis quality of life questionnaire (MiniRQLQ). Postnasal drip and cough symptoms were assessed using a 4-point scale. RESULTS: The mean pretreatment rTNSS was 7.8 (95% CI, 7.5-8.1). The significant rTNSS treatment effect at 3 months (-4.2 [95% CI, -4.6 to -3.8]; p < 0.001) was sustained through 2 years (-4.5 [95% CI, -5.0 to -3.9]; p < 0.001), a 57.7% improvement. At 2 years, the proportion of patients with a minimal clinically important difference (MCID) of ≥30% improvement in rTNSS from baseline was 80.0% (95% CI, 71.4%-86.5%). Individual postnasal drip and cough symptom scores were significantly improved from baseline through 2 years. The proportion of patients who reached the MCID for the MiniRQLQ (≥0.4-point improvement) at 2 years was 77.4% (95% CI, 68.5%-84.3%). Of 81 patients using chronic rhinitis medications at baseline, 61.7% either stopped all medication use (28.4%) or stopped or decreased (33.3%) use of ≥1 medication class at 2 years. No device/procedure-related serious adverse events were reported throughout 2 years. CONCLUSION: TCRF neurolysis of the PNN resulted in sustained improvements in chronic rhinitis symptom burden and quality of life through 2 years, accompanied by a substantial decrease in medication burden. LEVEL OF EVIDENCE: 4 Laryngoscope, 134:2077-2084, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Lee JT, Abbas GM, Charous DD, et al. Two-Year Outcomes After Radiofrequency Neurolysis of Posterior Nasal Nerve in Chronic Rhinitis. Laryngoscope. 2023. PMID: 37916848. doi:10.1002/lary.31120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。